Patients with FHH3 often present with mild hypercalcemia that is usually detected incidentally during routine blood tests. Most individuals do not exhibit symptoms, but when symptoms do occur, they may include fatigue, muscle weakness, and mild cognitive disturbances. Unlike other hypercalcemic conditions, FHH3 does not typically lead to kidney stones or bone abnormalities.

The diagnostic workup for FHH3 involves a combination of clinical evaluation, laboratory tests, and genetic testing. Blood tests will show elevated calcium levels, while urine tests will reveal low calcium excretion. Parathyroid hormone (PTH) levels are usually normal or slightly elevated. Genetic testing can confirm the diagnosis by identifying mutations in the CASR, GNA11, or AP2S1 genes, which are associated with different types of familial hypocalciuric hypercalcemia.

There is no specific treatment required for FHH3, as the condition is generally benign and asymptomatic. Management focuses on monitoring calcium levels and ensuring that patients do not receive unnecessary treatments for hypercalcemia, such as parathyroid surgery, which is ineffective in FHH3. Patients should be educated about the nature of the disorder and reassured about its benign course.

The prognosis for individuals with FHH3 is excellent. The condition is typically lifelong but does not lead to significant health issues or complications. Patients can expect to lead normal, healthy lives without the need for medical intervention related to their calcium levels.

FHH3 is caused by mutations in the AP2S1 gene, which plays a role in calcium sensing and regulation. This gene mutation affects the calcium-sensing receptor (CaSR) pathway, leading to altered calcium homeostasis. The condition is inherited in an autosomal dominant manner, meaning that a child has a 50% chance of inheriting the disorder if one parent is affected.

FHH3 is a rare condition, and its exact prevalence is not well-documented. It is part of a group of disorders known as familial hypocalciuric hypercalcemia, which collectively are estimated to affect about 1 in 78,000 individuals. FHH3 is less common than the other types, FHH1 and FHH2.

The pathophysiology of FHH3 involves a disruption in the normal function of the calcium-sensing receptor (CaSR), which is crucial for maintaining calcium balance in the body. Mutations in the AP2S1 gene impair the receptor's ability to regulate calcium levels, leading to increased reabsorption of calcium in the kidneys and elevated blood calcium levels.

There are no known preventive measures for FHH3, as it is a genetic condition. Genetic counseling may be beneficial for affected families to understand the inheritance pattern and the likelihood of passing the condition to offspring.

Familial Hypocalciuric Hypercalcemia Type 3 is a rare genetic disorder characterized by elevated blood calcium levels and low urinary calcium excretion. It is generally benign and asymptomatic, requiring no specific treatment. Diagnosis is confirmed through genetic testing, and the condition is inherited in an autosomal dominant pattern. Patients with FHH3 can expect a normal life expectancy without significant health complications.

If you or a family member has been diagnosed with Familial Hypocalciuric Hypercalcemia Type 3, it's important to understand that this condition is typically harmless and does not require treatment. Regular monitoring of calcium levels is recommended, but you can continue to live a healthy and active life. If you have concerns about the genetic aspects of the disorder, consider speaking with a genetic counselor for more information.